Trial · NCT06446531
Prevention of Progression of Prediabetes, Obesity and CV Risk
NCT06446531, Phase 1, Recruiting, The University of Texas Health Science Center at San Antonio
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prevention of Progression of Prediabetes, Obesity and CV Risk. Trials, record NCT06446531. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06446531
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prevention of Progression of Prediabetes, Obesity and CV Risk
- NCT number
- NCT06446531
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 64 participants, estimated
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Conditions
- Pre-Diabetes, Weight, Body, Cardiovascular Diseases
- Interventions
- Placebo, Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin, Actos
- First posted
- 2024-06-06
- Last updated
- 2025-11-12
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hemoglobin A1c Level (HBA1c) | Baseline and 6 months | Percentage of glycated hemoglobin level in blood |
| Secondary | Body Mass Index (BMI) | Baseline and 6 months | Measure of body fat based on height and weight that applies to adult men and women |
| Secondary | Percentage of Body Fat Composition | Baseline and 6 months | Measurement of body fat using a DEXA scan |
| Secondary | Left Ventricular Function | Baseline and 6 months | Cardiac function is measured by left-ventricular function measured using cardiac MRI and expressed as a percentage |
| Secondary | Measure of phosphocreatine k-value | Baseline and 6 months | A skeletal muscle bioenergetic measurement using skeletal muscle MRI/MRS |
| Secondary | Measure of oxidative capacity | Baseline and 6 months | A skeletal muscle bioenergetic measurement using skeletal muscle MRI/MRS |
| Secondary | Measure of intramyocellular lipids (IMCL) | Baseline and 6 months | A skeletal muscle bioenergetic measurement using skeletal muscle MRI/MRS |
| Secondary | Measure of extramyocellular lipids (EMCL) | Baseline and 6 months | A skeletal muscle bioenergetic measurement using skeletal muscle MRI/MRS |
| Secondary | Patient Reported Outcomes (PROMIS) | Baseline and 6 months | A survey used to assess physical function. Subjects will rank 20 questions from a scale of 1 - 5, with 5 being the highest physical function and 1 being the lowest. The score will be added up, and the Raw score will be converted to T-Score using the PROMIS Adult v2.0 Physical Function 20a Short Form Conversion Table. The range of T-scores is 12.1-62.5. A higher score indicates higher physical function. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06446531
GET https://conductscience.org/api/trials/v1/NCT06446531/registered